|
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer |
Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, Shepherd FA, Leighl NB |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, Shepherd FA, Leighl NB. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Annals of Oncology 2011; 22(8): 1805-1811 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /economics /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /mortality; Cost-Benefit Analysis; Disease-Free Survival; Humans; Lung Neoplasms /drug therapy /mortality; Quality of Life; Quinazolines /adverse effects /economics /therapeutic use; Randomized Controlled Trials as Topic; Taxoids /adverse effects /economics /therapeutic use AccessionNumber 22011001461 Date bibliographic record published 14/12/2011 |
|
|
|